en · de · es · fr · pt
melanotan-2-notes.peptides9000.com › Topic › Storage, Verification And Regulatory Status — Worked Examples

Storage, Verification And Regulatory Status — Worked Examples

By Editorial Desk · published 2026-01-26 · last reviewed 2026-02-19 · Topic

The short version of research chemical fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2026-02-19 and is reviewed periodically as new material appears.

Storage, Verification and Regulatory Status

Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.

Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.

Melanotan-2 Identity and Receptor Pharmacology

Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.

Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.

Melanotan-2 at a glance

PropertyValueNotes
Typical storage temperature-20 °C or belowFor the lyophilised powder, desiccated
Storage formSealed vial, protected from lightAmber glass or foil-wrapped containers
Reconstituted stabilityShort, refrigerateDegradation accelerates in solution
Typical analytical methodReversed-phase HPLC with mass spectrometryPurity assessment plus identity confirmation
Common synonymsMelanotan II, MT-IIAlso written melanotan-2

Handling, Storage, and Analytical Verification

Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.

Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.

Related pages on this site

Background and Receptor Mechanism

Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.

Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.

Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.

Reference notes

In a clinic, up to 80% of patients are women, but this might not necessarily reflect the gender distribution in the entire population. According to Joel Paris, the primary reason for gender disparities in clinical settings is that women are more likely to develop symptoms that prompt them to seek help. Statistics indicate that twice as many women as men in the community experience depression. Conversely, men more frequently meet criteria for substance use disorder and psychopathy, but tend not to seek treatment as often. Additionally, men and women with similar symptoms may manifest them differently. Men frequently exhibit behaviors such as increased alcohol consumption and criminal activity, while women may internalize anger, leading to conditions like depression and self-harm, such as cutting or overdosing. Hence, the gender gap observed in antisocial personality disorder and borderline personality disorder, which may share similar underlying pathologies but present different symptoms influenced by gender. There are also sex differences in personality traits and Axis I and II comorbidity. Men with BPD are more likely to use substances recreationally, have explosive temper, high levels of novelty seeking and have (especially) antisocial, narcissistic, passive–aggressive or sadistic personality traits (male BPD being characterised by antisocial overtones). Women with BPD are more likely to have eating, mood, anxiety, and post-traumatic stress disorders.

== Taxonomy == At one time, all yellow or golden chanterelles in western North America had been classified as Cantharellus cibarius. Using DNA analysis, they have since been shown to be a group of related species. In 1997, the Pacific golden chanterelle (C. formosus) and C. cibarius var. roseocanus were identified, followed by C. cascadensis in 2003, C. californicus in 2008, and C. enelensis in 2017. C. cibarius var. roseocanus occurs in the Pacific Northwest in Sitka spruce forests, as well as Eastern Canada in association with Pinus banksiana.

== Adverse effects == Gastrointestinal adverse effects such as nausea and abdominal pain are extremely uncommon, and their frequency is substantially lower than with ibuprofen use. Increase in risk-taking behavior is possible. According to the U.S. Food and Drug Administration (FDA), the drug may cause rare and possibly fatal skin reactions such as Stevens–Johnson syndrome and toxic epidermal necrolysis, Rechallenge tests and an analysis of American but not French pharmacovigilance databases indicated a risk of these reactions. In clinical trials for osteoarthritis, the number of participants reporting adverse effects was similar for those on paracetamol and on placebo. However, the abnormal liver function tests (meaning there was some inflammation or damage to the liver) were almost four times more likely in those on paracetamol, although the clinical importance of this effect is uncertain. After 13 weeks of paracetamol therapy for knee pain, a drop in hemoglobin level indicating gastrointestinal bleeding was observed in 20% of participants, this rate being similar to the ibuprofen group. Due to the absence of controlled studies, most of the information about the long-term safety of paracetamol comes from observational studies. These indicate a consistent pattern of increased mortality as well as cardiovascular (stroke, myocardial infarction), gastrointestinal (ulcers, bleeding) and renal adverse effects with increased dose of paracetamol. Use of paracetamol is associated with 1.9 times higher risk of peptic ulcer.

He also stated that "Nations should not be punished in place of terrorists." According to Radio Farda's website, when the news of the attacks was released, some Iranian citizens gathered in front of the Embassy of Switzerland in Tehran, which serves as the protecting power of the United States in Iran, to express their sympathy, and some of them lit candles as a symbol of mourning. Radio Farda's website also states that in 2011, on the anniversary of the attacks, the United States Department of State published a post on its blog, in which the Department thanked the Iranian people for their sympathy and stated that it would never forget Iranian people's kindness. After the attacks, both the President and the Supreme Leader of Iran condemned the attacks. The BBC and Time magazine published reports on holding candlelit vigils for the victims by Iranian citizens on their websites. According to Politico Magazine, following the attacks, Ali Khamenei, the Supreme Leader of Iran, "suspended the usual 'Death to America' chants at Friday prayers" temporarily.

In a triple quadrupole mass spectrometer there are three quadrupoles. The first quadrupole termed "Q1" can act as a mass filter and transmits a selected ion and accelerates it towards "Q2" which is termed a collision cell. The pressure in Q2 is higher and the ions collides with neutral gas in the collision cell and are fragmented by CID. The fragments are then accelerated out of the collision cell and enter Q3 which scans through the mass range, analyzing the resulting fragments (as they hit a detector). This produces a mass spectrum of the CID fragments from which structural information or identity can be gained. Many other experiments using CID on a triple quadrupole exist such as precursor ion scans that determine where a specific fragment came from rather than what fragments are produced by a given molecule.

Sources: en.wikipedia.org

Reference notes

Similar effects of compound 22 were found for amphetamine- and cocaine-induced stereotypy in normal mice and TAAR1 knockout mice. On the basis of the preceding findings, it was concluded that compound 22 augments psychostimulant-induced hyperlocomotion in a manner that is partially or fully independent of TAAR1 antagonism. The biological targets and mechanisms of compound 22 mediating these effects are unknown.

==== Distribution ==== The volume of distribution of suvorexant is approximately 49 L. It crosses the blood–brain barrier and distributes into the central nervous system. Suvorexant has high plasma protein binding (99.5%). It is bound to albumin and α1-acid glycoprotein (orosomucoid).

According to Google patent search, Masliah's name appears on 28 patents, including several patents filed by Prothena Biosciences, as well as earlier patents filed in conjunction with UCSD for drugs that target synucleopathies. Research trials on the drugs cerebrolysin and minzasolmin were also found to be based on questionable data from Masliah's lab. Masliah co-authored 21 papers on the pig brain extract cerebrolysin, eight of which have been discovered to have issues. Cerebrolysin is marketed as containing "neurotrophic peptides" but researchers using high performance liquid chromatography found that it does not contain peptides, and is largely composed of amino acids and salt, with some trace protein fragments. Some of the fraudulent papers on cerebrolysin co-authored by Masliah appear to have been quite influential in boosting interest in cerebrolysin, which is used today in countries like Russia to treat stroke, dementia, and other conditions. Masliah received funding for many of his cerebrolysin studies from the maker of cerebrolysin, EVER Pharma, and collaborated with Herbert Moessler, former general manager at EVER Pharma, who incidentally has 19 of his own papers flagged for anomalies. Moessler and Masliah started a company, Neuropore, to investigate the drug minzasolmin in 2008. On December 16, 2024 UCB reported that a phase II clinical trial on minzasolmin involving 496 people showed that minzasolmin failed to demonstrate superiority over placebo in both primary and secondary endpoints. Masliah has not publicly commented on any of the findings against him.

The process required pressing tungsten powder into bars, then several steps of sintering, swaging, and then wire drawing. It was found that very pure tungsten formed filaments that sagged in use, and that a very small "doping" treatment with potassium, silicon, and aluminum oxides at the level of a few hundred parts per million (so-called AKS tungsten) greatly improved the life and durability of the tungsten filaments. The predominant mechanism for failure in tungsten filaments even now is grain boundary sliding accommodated by diffusional creep. During operation, the tungsten wire is stressed under the load of its own weight and because of the diffusion that can occur at high temperatures, grains begin to rotate and slide. This stress, because of variations in the filament, causes the filament to sag nonuniformly, which ultimately introduces further torque on the filament. It is this sagging that inevitably results in a rupture of the filament, rendering the incandescent lightbulb useless.

=== Processing === Synthesis and processing involves the creation of a material with the desired micro-nanostructure. A material cannot be used in industry if no economically viable production method for it has been developed. Therefore, developing processing methods for materials that are reasonably effective and cost-efficient is vital to the field of materials science. Different materials require different processing or synthesis methods. For example, the processing of metals has historically defined eras such as the Bronze Age and Iron Age and is studied under the branch of materials science named physical metallurgy. Chemical and physical methods are also used to synthesize other materials such as polymers, ceramics, semiconductors, and thin films. As of the early 21st century, new methods are being developed to synthesize nanomaterials such as graphene.

Sources: en.wikipedia.org

Notes from published material

In September 2024, following the resolution of a prolonged pay dispute, it was announced that the term "junior doctor" within the NHS would be replaced with "resident doctor." This change was set to take effect on Wednesday, 18 September 2024.

Opioids bind to specific opioid receptors in the nervous system and other tissues. There are three principal classes of opioid receptors, μ, κ, δ (mu, kappa, and delta), although up to seventeen have been reported, and include the ε, ι, λ, and ζ (Epsilon, Iota, Lambda and Zeta) receptors. Conversely, σ (Sigma) receptors are no longer considered to be opioid receptors because their activation is not reversed by the opioid inverse-agonist naloxone, they do not exhibit high-affinity binding for classical opioids, and they are stereoselective for dextro-rotatory isomers while the other opioid receptors are stereo-selective for levo-rotatory isomers. In addition, there are three subtypes of μ-receptor: μ1 and μ2, and the newly discovered μ3. Another receptor of clinical importance is the opioid-receptor-like receptor 1 (ORL1), which is involved in pain responses as well as having a major role in the development of tolerance to μ-opioid agonists used as analgesics. These are all G-protein coupled receptors acting on GABAergic neurotransmission.

Morphine, the archetypal opioid, and other opioids (e.g., codeine, oxycodone, hydrocodone, dihydromorphine, pethidine) all exert a similar influence on the cerebral opioid receptor system. Buprenorphine is a partial agonist of the μ-opioid receptor, and tramadol is a serotonin–norepinephrine reuptake inhibitor (SNRI) with weak μ-opioid receptor agonist properties. Tramadol is structurally closer to venlafaxine than to codeine and delivers analgesia by not only delivering "opioid-like" effects (through mild agonism of the μ-opioid receptor) but also by acting as a weak but fast-acting serotonin releasing agent and norepinephrine reuptake inhibitor. Tapentadol, with some structural similarities to tramadol, presents what is believed to be a novel drug working through two (and possibly three) different modes of action in the fashion of both a traditional opioid and as an SNRI. The effects of serotonin and norepinephrine on pain, while not completely understood, have had causal links established and drugs in the SNRI class are commonly used in conjunction with opioids (especially tapentadol and tramadol) with greater success in pain relief. Dosing of all opioids may be limited by opioid toxicity (e.g., confusion, respiratory depression, myoclonic jerks, and pinpoint pupils), seizures (particularly from tramadol), but opioid-tolerant individuals usually have higher dose ceilings than patients without tolerance. Opioids, while very effective analgesics, may have some unpleasant side-effects.

Many foods are rich in the amino acids and nucleotides imparting umami. Naturally occurring glutamate can be found in meats and vegetables. Inosine (IMP) comes primarily from meats and guanosine (GMP) from vegetables. Mushrooms, especially dried shiitake, are rich sources of umami flavor from guanylate. Smoked or fermented fish are high in inosinate, and shellfish in adenylate. Protein in food is tasteless, however processes such as fermentation, curing, or heat treatment release glutamate and other amino acids. Generally, umami taste is common to foods that contain high levels of L-glutamate, IMP and GMP, most notably in fish, shellfish, cured meats, meat extracts, mushrooms, vegetables (e.g., ripe tomatoes, Chinese cabbage, spinach, celery, etc.), green tea, hydrolyzed vegetable protein, and fermented and aged products involving bacterial or yeast cultures, such as cheeses, shrimp pastes, fish sauce, soy sauce, natto, nutritional yeast, and yeast extracts such as Vegemite and Marmite. Studies have shown that the amino acids in breast milk are often the first encounter humans have with umami. Glutamic acid makes up half of the free amino acids in breast milk.

In ecological studies, biomass refers to the total amount of biological organisms that are present in a given environment or ecosystem. It may encompass the entirety of biological matter, or a subset of species or individuals. It is typically expressed as the total weight of carbon that is contained within the chosen group of organisms. A 2017 estimate of the total amount of biomass within the biosphere is approximately 550 gigatons of carbon, with a significant majority of this being terrestrial plants (approx. 450 Gt C). To calculate that, remote sensing techniques such as the Normalized difference vegetation index (NDVI), is commonly used to estimate biomass over large scales.

Sources: en.wikipedia.org

Frequently asked questions

How should the powder be stored?

The lyophilised solid is best kept cold, dry and dark, typically at minus twenty degrees Celsius. Moisture and repeated warming cycles are the main causes of degradation. Solutions prepared from the powder are less stable and are normally used quickly.

Which analytical methods confirm identity?

Reversed-phase liquid chromatography assesses purity, while mass spectrometry confirms molecular mass and detects sequence errors. Amino acid analysis and peptide mapping add structural detail. These techniques are complementary rather than interchangeable.

What is its status in sport and medicines?

It is listed as a prohibited peptide hormone by the World Anti-Doping Agency. No medicines regulator has approved it for human use. Import and sale rules vary by country.

What is melanotan-2 chemically?

It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.

Network